Coherus BioSciences Gets FDA Approval for Loqtorzi, Chemotherapy Combination
By Sabela Ojea
Coherus BioSciences and Shanghai Junshi Biosciences said the U.S. Food and Drug Administration approved its Loqtorzi antibody to treat nasopharyngeal cancer when used with chemotherapy.
The biotechnology companies said Loqtorzi said is aimed at patients with metastatic nasopharyngeal cancer.
The FDA backed Loqtorzi in combination with chemotherapy drugs cisplatin and gemcitabine.
Loqtorzi is expected to be available in the U.S. in the first quarter of 2024.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 27, 2023 15:54 ET (19:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy